Vischer with Proteomedix on Immunovia’s licensing
Vischer advised Proteomedix, a Swiss biotech subsidiary of Onconetix, on a licensing agreement with Swedish pancreatic cancer diagnostics company Immunovia.
The agreement
Under the terms of the agreement, Proteomedix will supply Immunovia with master cell lines for three of the five biomarkers included in the PancreaSure test and grant a license to its core manufacturing intellectual property, enabling Immunovia to produce the associated reagents.
In exchange, Immunovia will make payments of USD 700,000 in 2025 and 2026, along with a 3% royalty on net sales of PancreaSure and related products from 2026 through 2032.
The Vischer team
The Vischer lineup working on the matter included partner Christian Wyss (corporate/M&A, pictured) and associate Rahel Widmer (corporate/M&A).
